If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

RED LODGE, Mont. – Red Lodge Mountain announced the reopening of the Willow Creek chair after completing maintenance and ...

Weeks after KSAT’s Know My Neighborhood series highlighted safety concerns on a street in Denver Heights, the City of San ...

Crude prices posted a second consecutive weekly gain as prices were supported by renewed expectations of tighter supplies from sanctions on Iran and new output plans from OPEC+. West Texas ...

Big raises slowed for the second week in a row. Only a handful of rounds hit nine digits this week, although a large ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

A Texas state trooper accused of wrongfully killing a man in Converse after a pursuit exercised his right to remain silent ...

California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing.

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...